Intervacc AB Stock

IVACC

SE0009607252

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm 13:00:00 2026-10-28 EDT			5-day change	1st Jan Change
0.7850 ^SEK	+1.42%		-6.66%	-15.04%

08-20	Intervacc AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-20	Calendar Thursday, August 20	FW

Analysts' recommendations: Intervacc AB

24-05-20	Penser reiterates motivated value for Intervacc - report met expectations	FW
24-02-21	Penser lowers Intervacc's motivated value	FW
23-11-17	Penser makes minor estimate adjustments in Intervacc	FW
23-05-04	Penser lowers its motivated value for Intervacc to SEK 26-28 (48-54)	FW
23-02-20	Penser halves the motivated value for Intervacc - which falls on the stock exchange	FW

More recommendations

Managers and Directors: Intervacc AB

Manager	Title	Age	Since
Carl-Johan Dalsgaard CEO	Chief Executive Officer	70	2026-02-04
Jan Persson DFI	Director of Finance/CFO	-	2020-02-05
Andrew Waller CTO	Chief Tech/Sci/R&D Officer	-	2020-06-10

Director	Title	Age	Since
Emil Billbäck CHM	Chairman	56	2026-05-12
Carl Erik Mathias Uhlén BRD	Director/Board Member	72	2023-12-31
Björn Ingemar Odlander BRD	Director/Board Member	68	2024-12-31

More insiders

Intervacc AB is a Sweden-based biotechnology company. It develops vaccines based on recombinant proteins for animal health care. The Companyâ€™s candidate vaccine against strangles Strangvac consists of soluble recombinant proteins and devoids any living infectious agent. The Company operates through two subsidiaries: Nord Vacc Lakemedel AB and Mybac-Vettech AB. Nord Vacc Lakemedel AB markets and distributes veterinary vaccines, pharmaceuticals and vitamins on European market. It offers assortment of fur animal vaccines, the Febrivac range, as well as swine vaccines for Swedish and Danish markets. Mybac-Vettech AB is a technology platform that focuses on diagnostics in the Swedish animal health market and offers bacteriological and mycological analyses.

Employees

Sector

Biotechnology & Medical Research

Calendar

11-11 Earnings release - Q3 2026

More about the company

Quotes

Date	Price	Change	Volume
26-10-28	SEK 0.7850	+1.42%	263,145
26-10-27	SEK 0.7740	-4.68%	811,109
26-10-26	SEK 0.8120	-4.13%	197,384
26-10-23	SEK 0.8470	+1.93%	171,731
26-10-22	SEK 0.8310	-1.19%	471,319

Delayed Quote Nasdaq Stockholm

More quotes

EPS Estimates

Evolution of Analysts' Estimates - EPS - Intervacc AB

Revisions to estimates

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Intervacc AB

Company calendar

Market Cap	268M 26.98M 24.2M 22.38M 20.27M 37.86M 2.57B 38.32M 107M 1.34B 101M 99.09M 4.27B	P/E 2026 *	-0.7x	P/E 2027 *	-0.7x
Enterprise Value	179M 18M 16.15M 14.93M 13.52M 25.27M 1.71B 25.57M 71.11M 897M 67.55M 66.13M 2.85B	EV / Sales 2026 *	8.5x	EV / Sales 2027 *	6.88x
Free-Float	81.07%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Nasdaq Stockholm	IVACC	Delayed
CBOE		Real-time
Deutsche Boerse AG	2E9	Delayed
Börse Stuttgart	2E9	Delayed
CBOE		Real-time

08-20	Intervacc AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-20	Calendar Thursday, August 20	FW
07-30	Intervacc Submits Type Ii Variation Application to Ema Seeking 12-Month Duration of Immunity for Strangvac	CI
07-30	Intervacc Seeks EU Regulatory Approval to Extend Horse Vaccine's Immunity Duration	MT
07-29	Intervacc Gets Special Approval to Send Equine Vaccine to New Zealand	MT
07-29	Intervacc AB Publ Makes First Export Of Strangvac To New Zealand Under Special Circumstances Permit	CI
05-22	Intervacc AB Completes Successful Evaluation of Us Strain of Strangles Pathogen Ahead of Clinical Trials	CI
05-15	Sweden's Intervacc Elects New Chair	MT
05-15	Appoints Emil Billbäck as chairman	RE
05-13	Intervacc elects Emil Billbäck as chairperson of board	RE
05-13	Intervacc AB Announces Board Changes	CI
05-13	Intervacc Q1 net sales down at SEK 3.4 million	RE
05-13	Intervacc AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

09-15	Intervacc to present at upcoming International Healthcare Conference	AQ
09-01	Intervacc: Highlights from DNB Carnegie’s Micro Cap Day	AQ
08-24	Intervacc (Q2 Review): Key catalysts nearing	AQ
08-21	Intervacc: In the right direction – Q2 review	AQ
08-20	Intervacc (Q2 initial take): Few surprises – all eyes on the label extension	AQ

1 day	+1.42%
1 week	-6.66%
Current month	-22.58%
1 month	-16.04%
3 months	-36.90%
6 months	-34.58%
Current year	-15.04%

Intervacc AB Stock

Stocks

IVACC

SE0009607252

Biotechnology & Medical Research

Valuation: Intervacc AB

Chart: Intervacc AB

Latest news: Intervacc AB

Analysts' recommendations: Intervacc AB

Press Releases: Intervacc AB

Quotes and Performance

Price Extremes

Managers and Directors: Intervacc AB

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Quarterly revenue - Rate of surprise

1 week	0.77	0.86
1 month	0.77	1.04
Current year	0.57	1.46
1 year	0.57	1.46
3 years	0.57	10.46
5 years	0.57	76
10 years	0.57	95.5

Date	Insider	Type	Main position	Quantity	% Market Cap.
2/23/25	Jan Persson	Free	Chief Financial Officer	929,208	1.2269%
2/17/25	Jonas Sohlman	Buy	Chief Executive Officer	135,000	0.1783%
2/17/25	Jan-Ingmar Flock	Sell	Chief Executive Officer	278,820	0.3681%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
INTERVACC AB	+1.42%	-6.66%	-18.23%	-86.11%	26.55M
WUXI APPTEC CO., LTD.	+0.65%	-3.36%	+36.98%	+60.50%	63.48B
ARGENX SE	+1.76%	+1.27%	+11.82%	+81.21%	54.55B
LONZA GROUP AG	-0.94%	+0.99%	+10.45%	+100.19%	53.59B
IQVIA HOLDINGS INC.	+2.76%	+0.87%	+27.92%	+55.07%	44.75B
BEONE MEDICINES AG	+2.00%	-3.39%	+17.83%	+119.04%	41.62B
REVOLUTION MEDICINES, INC.	+1.34%	-2.86%	+224.43%	+914.08%	39.91B
CELLTRION, INC.	+0.64%	-3.95%	+11.15%	+45.57%	32.47B
GENMAB A/S	+29.06%	+47.63%	+107.12%	+92.73%	26.7B
WUXI BIOLOGICS (CAYMAN) INC.	+3.72%	-6.23%	+26.01%	-2.99%	23.36B
Average	+4.24%	-1.22%	+45.55%	+137.93%	38.05B
Weighted average by Cap.	+3.23%	-0.29%	+48.18%	+161.45%

	2026 *	2027 *
Net sales	21M 2.12M 1.9M 1.76M 1.59M 2.97M 202M 3.01M 8.36M 106M 7.95M 7.78M 335M	30M 3.02M 2.71M 2.51M 2.27M 4.25M 288M 4.3M 11.95M 151M 11.35M 11.11M 479M
Net income	-82.45M -8.31M -7.46M -6.9M -6.25M -11.67M -792M -11.81M -32.84M -414M -31.2M -30.54M -1.32B	-83.65M -8.43M -7.57M -7M -6.34M -11.84M -803M -11.98M -33.32M -420M -31.65M -30.98M -1.33B
Net Debt	-89M -8.97M -8.05M -7.44M -6.74M -12.59M -855M -12.75M -35.45M -447M -33.68M -32.96M -1.42B	-61M -6.15M -5.52M -5.1M -4.62M -8.63M -586M -8.74M -24.3M -307M -23.08M -22.59M -973M